Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that new data from the company’s HIV research and development program will be presented at the 23rd International AIDS Conference (AIDS 2020: Virtual) from July 6-10. The breadth of data presented at the meeting, along with Gilead-led symposia and workshops, reflect the company’s commitment to advancing the scientific understanding of HIV prevention, treatment and cure strategies. “Continued scientific inn

Gilead Sciences Demonstrates Commitment to Scientific Innovation In HIV With New Prevention, Treatment and Cure Research Data Presented At AIDS 2020: Virtual

President Donald Trump’s “amazing deal” secures a stockpile of Gilead Sciences drug,  in a move that could mean patients around the world will not receive the coronavirus treatment

U.S. Buys The World Supply Of Breakthrough Coronavirus Drug Remdesivir

President Trump's deal to hoover up the world supply of remdesivir is a chilling warning of what could happen when the first coronavirus vaccine is ready to be rolled out.

Trump's remdesivir deal serves as a warning over future vaccine

The US has bought up almost the entire global supply of one of two drugs proven to treat coronavirus.

US buys up almost entire world supply of coronavirus drug

Gilead (GILD) prices experimental coronavirus drug, remdesivir, at $390 per vial.

Gilead Prices Coronavirus Drug Remdesivir at $390 Per Vial

No other country will be able to buy remdesivir, which can help recovery from Covid-19, for next three months at least

US buys up world stock of key Covid-19 drug

In the U.S., a health insurer insurer should be billed $3,120 per treatment course.

Gilead Fixes the Price of COVID-19 Drug Remdesivir; the Government Secures the Bulk of Its Supply

Gilead Sciences said Monday its experimental coronavirus treatment, remdesivir, will cost $3,120 per U.S. patient with insurance for a five-day course.

Is Gilead's Coronavirus Drug On Track To Become A Mega-Blockbuster?

U.S. taxpayers in part financed Gilead Sciences, Inc. (NASDAQ: GILD) and the National Institute of Health’s trial of its remdesivir.

Gilead CEO talks remdesivir pricing

Gilead Sciences Inc on Monday priced its COVID-19 antiviral remdesivir at $2,340 per patient for wealthier nations and agreed to send nearly all of its supply of the drug to the United States over the next three months.

Gilead prices COVID-19 drug remdesivir at $2,340 per patient in developed nations

GILD vs. ILMN: Which Stock Is the Better Value Option?

GILD vs. ILMN: Which Stock Should Value Investors Buy Now?

GILD has remained rangebound absent news on remdesivir pricing in the US.

Gilead Finally Delivers On Remdesivir

Health officials said Monday that it will receive 500,000 treatment courses of Gilead Sciences Inc.'s GILD, +0.97% remdesivir through September that can then be purchased by U.S. hospitals.

HHS: 500,000 courses of Gilead Sciences' remdesivir to be available for sale

Gilead Sciences Inc. (NASDAQ: GILD) took another big step Monday in the fight against COVID-19 its treatment, remdesivir.

Gilead Moves Forward With Pricing Its COVID-19 Treatment

Gilead Sciences has released how much it’s going to charge for its COVID-19 drug remdesivir—and it’s not cheap.
Gilead Sciences has released how much it’s going to charge for its COVID-19 drug remdesivir—and it’s not cheap.

COVID-19 drug remdesivir will cost as much $3,120 in the United States

Clinical trials revealed the drug can help patients recover from the coronavirus faster.

US to buy 500,000 remdesivir coronavirus treatment courses at $2,340 each

Gilead Sciences, Inc. (NASDAQ: GILD) announced pricing Monday for its antiviral remdesivir, which has been granted  emergency use authorization by the FDA for treating COVID-19.

Gilead Announces Pricing Of Coronavirus Treatment Remdesivir: 'We Believe All Patients Will Have Access'

A typical patient on private insurance can expect to pay $3,120 for the Covid-19 drug.

Gilead Finally Reveals Remdesivir Pricing After Weeks Of Speculation

Gilead Sciences Inc has priced its COVID-19 drug candidate remdesivir at $2,340 for a five-day treatment in the United States and some other developed countries, it said on Monday, as it set the price for a single vial at $390.

Gilead prices COVID-19 drug candidate remdesivir at $2,340 per patient

"At the level we have priced remdesivir and with government programs in place, along with additional Gilead assistance as needed, we believe all patients will have access," Gilead CEO Daniel O'Day said in an open letter.

Gilead's coronavirus treatment remdesivir to cost $3,120 per U.S. patient with private insurance

Shares of Gilead Sciences Inc. GILD, -1.21% gained 1.1% in premarket trading on Monday after the drugmaker disclosed that remdesivir, its experimental COVID-19 treatment, will cost $2,340 for a course of treatment.

Gilead prices remdesivir at $2,340 for treatment in most of the developed world

Exelixis

Seagen

These companies have products, products, and more products to keep revenue flowing.

3 Biotech Stocks I’d Buy Right Now

Sell-side analysts are not giving Gilead a lot of credit for remdesivir.

Analysts Underestimate Gilead COVID-19 Treatment

Gilead's (GILD) experimental coronavirus drug, remdesivir, has been recommended for approval by the EMA's human medicines committee.

Gilead's (GILD) Remdesivir Gets CHMP Approval Recommendation

Gilead has indicated that it would be starting clinical trials for an inhaled version of Remdesivir shortly. While the wide-spectrum anti-viral drug is currently given intravenously for severe cases of Covid-19 in the hospital, the new delivery method could enable treatment at earlier stages of.

News for Gilead Sciences Stock (GILD)